Navigation Links
Amgen to Webcast 2011 Business Review Meeting on April 21
Date:4/14/2011

THOUSAND OAKS, Calif., April 14, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced that it will hold its Business Review Meeting on Thursday, April 21, 2011 at the Mandarin Oriental Hotel, 80 Columbus Circle, New York City, beginning at 8 a.m. Eastern Time. In the meeting, Kevin Sharer, chairman and CEO, Robert A. Bradway, president and COO, Roger M. Perlmutter, M.D., Ph.D., executive vice president, Research and Development, and Jonathan M. Peacock, executive vice president and CFO, will discuss the Company's strategy and long-term growth objectives, commercial performance and expectations, research and development innovation and pipeline progress, financial performance expectations and the Company's capital allocation plan.

The webcast will be available to members of the news media, investors and the general public and is expected to last approximately three hours.

The webcast of the meeting, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability, and webcast links are noted on Amgen's Investor Relations Events Calendar.  The webcast will be archived and available for replay at least 30 days after the event.

About Amgen

Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com.

CONTACT: Amgen, Thousand Oaks
David Polk, 805-447-4613 (media)
Arvind Sood, 805-447-1060 (investors)

(Logo:  http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)


'/>"/>
SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... 23, 2016 Diplomat Pharmacy, Inc. (NYSE: DPLO) announced ... Internship programs. The hands-on learning experience is a 12-week ... paid Fellowship and Internship programs ... Fellows and interns are provided optional housing free of ... at the Riverfront Residence Hall to foster communication ...
(Date:5/23/2016)... According to market research ... and Demand Forecast to 2022 - Industry Insights ... (Drug Discovery and Development, Proteomics, Clinical Testing, Environment ... and Biotechnology, Academic and Research Institute, Hospitals and ... mass spectrometry market was valued at ...
(Date:5/23/2016)... The World Health Organization (WHO) expanded the Intended Use of ... 13 years, and above. Effective immediately, the PrePex device, manufactured ... males in the 14 priority countries in Southern and ... circumcision device to receive WHO Prequalification on 31 May 2013. ... " The expanded use of PrePex for younger ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... 2016 , ... United Benefit Advisors (UBA), the nation’s leading ... & Co., Inc. Headquartered in Albany, New York, Austin & Co., Inc. ... and beyond. As an employee-owned company celebrating over 160 years of service, ...
(Date:5/24/2016)... CO (PRWEB) , ... May 24, 2016 , ... ... tied to family wealth and to housing, with more advantaged communities providing richer ... proposed five types of interventions: (a) school improvement policies; (b) school choice policies; ...
(Date:5/24/2016)... ... May 24, 2016 , ... How to Write Error Free Procedures, **Presented by ... , Human error is known to be the major cause of quality and production ... totally eliminated, many human performance problems can be prevented. , How to Write Error ...
(Date:5/24/2016)... ... ... Mental health watchdog Citizens Commission on Human Rights (CCHR) of ... Thomas Szasz, is continuing its protest against the use of electroshock (ECT) on children ... The opening of the exhibit follows CCHR’s recent protest at the annual convention of ...
(Date:5/24/2016)... ... (PRWEB) May 24, 2016 -- Grow Healthy Vending, LLC ... Joining the Grow Healthy Advisory Board team are Amanda Katchka, ... mission of our organization and bring talent, expertise and energy to ... continue to expand our footprint as the leader in healthy vending,” ...
Breaking Medicine News(10 mins):